Keyword: Jakafi

Incyte pens cancer I-O pact with UPenn cancer center

Just 12 months ago, Incyte was hit with a major trial setback when its JAK inhibition drug for solid tumors flopped a key test. Since then the biotech has been looking to I-O combos, and today it has broadened its reach with a new cancer immunotherapy deal with the University of Pennsylvania.

5. Gilead Sciences

Gilead Sciences could at one time do no wrong, but then sales of its hep C meds slowed and it hit some major trial setbacks. Now, the biotech faces increasingly loud questions about what its next Big Thing will be.

FierceBiotech’s Rotten Tomatoes

Welcome to our new annual feature that aims to name and shame those biopharmas and medical device companies that made an attempt at being ripe but turned out to be rotten.